- Impact of immunomodulatory drugs in treatment of primary myelofibrosis2015 | Faculty of Medicine in Hradec Králové
- Combination Therapy Using Invariant Natural Killer T Cells and Immunomodulatory Drugs in Multiple MyelomaPublication without faculty affiliation
- Inosine pranobex, effective immunomodulatory drug approved by the long-term clinical application; possible mechanisms of action2018 | Faculty of Medicine in Hradec Králové
- Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma2013 | First Faculty of Medicine
- Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide2015 | Faculty of Science
- Chemiluminiscence test in the laboratory valuation of the immunomodulative treatment2000 | First Faculty of Medicine
- Immunomodulatory therapy of respiratory diseases2009 | Second Faculty of Medicine
- Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study2010 | First Faculty of Medicine
- A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab2021 | First Faculty of Medicine
- Treatment possibilities of ipilimumab-induced thrombocytopenia-case study and literaure review2015 | Faculty of Medicine in Hradec Králové
- Basic principles of the treatment of hematological malignancies2013 | First Faculty of Medicine
- Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma2021 | Faculty of Medicine in Hradec Králové
- Cemiplimab in patients with metastatic of locally advanced cutaneous squamous-cell carcinoma2020 | Faculty of Medicine in Hradec Králové
- Treatment of relapsed and refractory multiple myeloma2021 | Faculty of Medicine in Hradec Králové
- Improving gait in patients with multiple sclerosis2022 | First Faculty of Medicine
- Thromboprophylaxis in monoclonal gammopathy2007 | First Faculty of Medicine
- Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment?2017 | First Faculty of Medicine
- New trends in the multiple myeloma treatment2019 | First Faculty of Medicine
- Clinical Trials in Myositis: Where Do We Stand?2021 | First Faculty of Medicine
- Advances in multiple myeloma therapy during two past decades2014 | First Faculty of Medicine
- Management of multiple sclerosis2017 | Faculty of Medicine in Pilsen
- Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society2020 | Faculty of Medicine in Hradec Králové
- A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma2020 | Faculty of Medicine in Hradec Králové
- Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy2014 | Faculty of Science
- Contemporary Treatment of Amyloid Heart Disease2015 | First Faculty of Medicine
- Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study2016 | Second Faculty of Medicine
- Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells2016 | First Faculty of Medicine
- Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN2017 | Second Faculty of Medicine
- HYCO-3, a dual CO-releaser/Nrf2 activator, reduces tissue inflammation in mice challenged with lipopolysaccharide2019 | First Faculty of Medicine